NCT04842812: Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2, Mesothelin+, MUC1, GPC3, LeY, AXL, EGFR, ROR1+, GD1/2, B7-H3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 

Comments are closed.

Up ↑